Extending the duration of first-line chemotherapy in metastatic breast cancer: A perspective review

Therapeutic Advances in Medical Oncology

Volumn 3, Issue 5, 2011, Pages 229-232

  Gennari, Alessandra ^a   D’amico, Mauro ^a   Corradengo, Davide ^a  

^a GALLIERA HOSPITAL   (Italy)

Author keywords

chemotherapy; duration; metastatic breast cancer; overall survival; progression free survival

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVANCED CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; HUMAN; METASTASIS; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION;

EID: 80054850335     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834011413423     Document Type: Review

References (19)

1. Alba E. Ruiz Borrego M. Margeli M. Rodriguez-Lescure A. Sanchez-Rovira P. Ruiz A. Mel-Lorenzo J.R. et al (2010) Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study. Breast Cancer Res Treat 122: 169–176.
2. Bertelli G. Garrone O. Bertolotti L. Occelli M. Conforti S. Marzano N. et al (2005) Maintenance hormone therapy with letrozole after first-line chemotherapy for advanced breast cancer. Oncology 68: 364–370.
3. Chia S.K. Speers C.H. D'yachkova Y. Kang A. Malfair-Taylor S. Barnett J. et al (2007) The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 110: 973–979.
4. Coates A.S. Byrne M. Bishop J.F. Forbes J.F. (1987) Intermittent versus continuous chemotherapy for breast cancer. N Engl J Med 314: 1490–1495.
5. Ejlertsen B. Pfeiffer P. Pedersen D. Mouridsen H.T. Rose C. Overgaard M. et al (1993) Decreased efficacy of cyclophosphamide, epirubicin and 5-fluoracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months. Eur J Cancer 29A: 527–531.
6. Falkson G. Gelman R.S. Pandya K.J. Osborne C.K. Tormey D. Cummings F.J. et al (1998) Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with breast cancer in complete remission following induction treatment. J Clin Oncol 16: 1669–1676.
7. French Epirubicin Study Group (2000) Epirubicin-based chemotherapy in metastatic breast cancer patients: Role of dose intensity and duration of treatment. J Clin Oncol 18: 3115–3124.
8. Geels P. Eisenhauer E. Bezjak A. et al (2000) Palliative effect of chemotherapy: Objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol 18: 2395–2405.
9. Gennari A. Amadori D. de Lena M. Nanni M. Bruzzi M. Lorusso V. et al (2006) Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. J Clin Oncol 24: 3912–3917.
10. Gennari A. Conte P. Rosso R. Orlandini C. Bruzzi P. (2005) Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 104: 1742–1750.
11. Gennari A. Stockler M. Puntoni M. Sormani M. D'amico M. de Censi A. et al (2011) Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol ePub ahead of print.
12. Gregory R.K. Powles T.J. Chang J.C. Ashley S. (1997) A randomized trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast. Eur J Cancer 33: 2194–2197.
13. Harris A.L. Cantwell B.M. Carmichael J. Wilson R. Farndon J. Dawe P. et al (1990) Comparison of short-term and continuous chemotherapy(mitozantrone) for advanced breast cancer. Lancet 335: 186–190.
14. Mayodromo J. Baena J.M. Cirera P. Sanchez-Rovira P. Godes M.J. Galan A. et al (2009) Final results of a randomised trial on the role of maintenance chemotherapy with weekly paclitaxel for patients with metastatic breast cancer. J Clin Oncol 27: 41s–41s. abstract 1001.
15. Muss H.B. Case L.D. Richards F.II. White D.R. Cooper M.R. Cruz J.M. et al (1991) Interrupted versus continuous chemotherapy in patients with metastatic breast cancer: The Piedmont Oncology Association. N Engl J Med 325: 1342–1348.
16. National Comprehensive Cancer Network (2010) Practice guidelines in oncology, v.2. Breast cancer. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
17. Nooji M.A. de Haes J.C.J.M. Beex L.V.A.M. Wildiers J. Klijn J. Becquart D. et al (2003) Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients: Clinical outcomes and oncologists’ preferences. Eur J Cancer 39: 614–621.
18. Stockler M. Wilcken N. Coates A. (1997) Chemotherapy for metastatic breast cancer – when is enough enough? Eur J Cancer 33: 2147–2148.
19. Stockler M.R. Wilcken N.J.C. Coates A.S. (2003) Chemotherapy for advanced breast cancer: How long should it continue? Breast Cancer Res Treat 81(Suppl. 1): S49–S52.